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Role of the NLRP3 inflammasome in the transient
release of IL-1β induced by monosodium urate
crystals in human fibroblast-like synoviocytes
Shu-cong Zheng1,2†, Xiao-xia Zhu1,2†, Yu Xue1,2, Li-hong Zhang3, He-jian Zou1,2, Jian-hua Qiu2,4*
and Qiong Liu2,3,5*
Abstract
Background: To investigate whether monosodium urate (MSU) crystals induce interleukin (IL)-1β in human
fibroblast-like synoviocytes (FLS), and whether the NLRP3 inflammasome is involved in the inflammatory mechanism.
Methods: Human FLS isolated from explants of synovial tissue were stimulated with MSU crystals (0.001 to 0.5 mg/ml)
for different time course (6 hours to 48 hours). The expressions of IL-1β, IL-6, TNF-α and NLRP3 were evaluated with
ELISA, Western blot and quantitative real-time PCR.
Results: Exposure of FLS to MSU crystals transiently induced a significant increase in IL-1β expression in culture medium
with a peak at 6 h. The mRNA level of IL-1β in the FLS cells had a similar pattern at this time point. Changes in IL-6 and
TNF-α expression were not observed. Simultaneously, intercellular pro-IL-1β was detected at 6 h. Furthermore,
MSU crystals also induced NLRP3 mRNA and protein expression at 6 h to 48 h after MSU treatment.
Conclusions: MSU crystals directly increased IL-1β and intercellular NLRP3 expression in FLS cells. It is suggested
that the NLRP3 inflammasome may be associated with IL-1β in FLS treated with MSU. Altogether, MSU could induce
production and release of IL-1β through the NLRP3 inflammasome in human synoviocytes.
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Background
Gout is one of inflammatory arthritis due to deposition
of monosodium urate (MSU) crystals in synovial fluid
and joints [1]. As demonstrated in vivo, MSU crystals
cause inflammation. When MSU crystals were injected
into the peritoneum in an animal model of acute gout, it
induced the production of proinflammatory cytokines
such as interleukin-1β (IL-1β) [2].
Although MSU is identified as a causative agent in
gout [3,4], the mechanisms underlying MSU crystal-
induced inflammation have only recently begun to be
understood [3,5]. Pro-inflammatory cytokines play a
critical role in the inflammatory reaction induced by
MSU-crystals [6,7]. It is suggested by several studies that
IL-1β, the pathological hallmark of the acute inflammatory
attack, is a key regulatory pro-inflammatory cytokine in
gout, which promotes a neutrophil influx into the syno-
vium and joint fluid [8,9]. Moreover, IL-1β also plays a
crucial role in driving the transition from the acute phase
of arthritis to the chronic irreversible phase [10].
IL-1β-dependent inflammation, occurring in a number of
diseases in addition to gout, depends on the MSU-induced
formation of a macromolecular nucleotide-binding domain-
like receptor protein 3 (NLRP3) inflammasome complex
[3,11-13]. The NLRP3 (also known as NALP3) inflamma-
some has been shown to form through homotypic interac-
tions between the CARD and PYD domains of NLRP3,
Pyrin and apoptosis-associated speck like protein (ASC).
After the NLRP3 inflammasome is formed, it converts
procaspase-1 to active caspase-1, which in turn cleaves
pro-IL-1β to active IL-1β. Although MSU has been
described as a causative agent in gout for more than 100
* Correspondence: jianhua.qiu@childrens.harvard.edu; liuqiong@fudan.edu.cn
†Equal contributors
2Institute of Rheumatology, Immunology and Allergy, Fudan University,
Shanghai, China
3Department of Anatomy, Histology and Embryology, Shanghai Medical
College of Fudan University, 138 Yixueyuan Road, Shanghai 200032, PR China
Full list of author information is available at the end of the article
© 2015 Zheng et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Zheng et al. Journal of Inflammation  (2015) 12:30 
DOI 10.1186/s12950-015-0070-7
years [14], its mechanism of action was not understood
until the discovery of NLRP3 a decade ago [15].
Accumulating evidence suggests that MSU crystal-
induced inflammation has undergone phagocytosis-
activated the NLRP3 inflammasome, which leads to
secretion of IL-1β from resident macrophages [16-18]. In
turn, this secretion can increase the production of IL-1β
and other inflammatory mediators further, and promote
the activation of synovial lining cells and phagocytes
[3,19]. Recent studies show that MSU crystals induce
synoviocytes to release CCL2 (monocyte chemoattractant
protein-1; MCP-1) and recruit monocytes/macrophages to
joints [20]. However, it is unclear whether MSU causes
synoviocytes to produce IL-1β, and if so, what the poten-
tial mechanisms are. The aim of the present study is to
address whether synoviocytes can activate transcriptional
levels of IL-1β, and secrete IL-1β after exposure to MSU
crystals. An additional aim is to explore the potential
underlying molecular mechanisms.
Materials
FLS isolation and culture
The study was approved by the Ethics Committees of
Huashan Hospital, Fudan University. Synovial tissues
were obtained from one patient, who had joint replace-
ment due to idiopathic femoral head necrosis. Synovial
fibroblasts were isolated from the synovial tissues by
enzymatic digestion. FLS were isolated from tissue
explants, as previously described [21]. In brief, synovium
tissues were rinsed several times in PBS, minced into
~1-mm pieces, placed in T25 flasks (Falcon, USA), and
maintained in DMEM supplemented with 10% heat-
inactivated fetal calf serum (FCS), 50 μg/ml strepto-
mycin, 50 U/ml penicillin, and 2 mmol/L glutamine
(10% FCS medium). At confluence, cells were harvested
(trypsin/EDTA) and seeded into new flasks. All experi-
ments were carried out with passage 4 through 8 FLS.
Reagents
MSU crystals were purchased from Alexis (Enzo Life
Sciences, USA). Cell culture reagents including media,
phosphate buffered saline (PBS), and Hank’s balanced
salts solution (HBSS), penicillin-streptomycin, glutamax,
and fetal calf serum (FCS) were obtained from Invitrogen
(USA). Polyclonal anti-pro-IL-1β, anti-NLRP3 antibody
was purchased from Santa Cruz Biotechnology (Santa
Cruz, USA).
Cytokine detection by ELISA
FLS were plated at 2.0 × 104 cells/well in a 24-well plate.
When they reached subconfluency, the medium was re-
moved, and fresh medium was applied along with MSU
(1, 10, 50, 100, 200, 500 ug/ml). The supernatants were
collected after stimulation with MSU for 6 h, 12 h, 24 h
and 48 h respectively. IL-1β, IL-6, and TNFα levels in the
supernatants were measured by ELISA (R&D Systems,
USA) according to the manufacturer’s protocol.
Quantitative real-time PCR
Total RNA was extracted using RNA Lyzol reagent
(EXcell Bio, Shanghai, China). cDNA was synthesized
with the Rever TraAceHqPCR RT Kit (TOYOBO. CO,
TLD, Japan). Quantitative real-time PCR was performed on
a 7500 Fast Real-Time PCR System (AB Applied Biosys-
tems, USA) using SYBRH Green Realtime PCR Master
Mix (TOYOBO. CO, TLD, Japan). The specificity of ampli-
fication was assessed for each sample by melting curve ana-
lysis. Relative quantification was performed using standard
curve analysis. The quantification data are presented as a
ratio to the control level. The Homo sapiens (hs) gene
specific primers used were as follows: IL-1β, 5′-TTGTTG
CTCCATATCCTGTCC-3′ (forward) and 5′-CACATGGG
ATAACGAGGCTT-3′ (reverse); IL-6, 5′-GGAGACTTGC
CTGGTGAA-3′ (forward) and 5′-GCATTTGTGGTTG
GGTCA-3′ (reverse); TNFα, 5′-CACTAAGAATTCAAA
CTGGGGC-3′ (forward) and 5′- GAGGAAGGCCTAA
GGTCCAC-3′ (reverse); NLRP3, 5′-TAAAGAGATGAGC
CGAAGTGGG-3′ (forward) and 5′-TCAATGCTGTCT
TCCTGGCA-3′ (reverse); GAPDH, 5′-ATGACCCCTTC
ATTGACC-3′ (forward) and antisense 5′-GAAGATGGT
GATGGGATTTC-3′ (reverse).
Western blot analysis
FLS were seeded in 6-well culture plates at a density of 1
× 106 cells/well. The cells were allowed to adhere for 24
hours, and then the cells were cultured in the medium
with 2% FCS and 50 μg/ml MSU crystals for 6 hours or 48
hours. The cells were disrupted in lysis buffer (20 mM Tris,
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1%
Triton X-100, 2.5 mM sodium pyrophosphate, and 1 mM
b-glycerophosphate) with 1 mM PMSF, 1 mg/ml leupeptin,
and 1 mM sodium orthovanadate (Sigma, USA). The con-
centrations of the extracted proteins were measured using
a BCA Protein Assay Kit (Thermo Fisher Scientific, USA).
Samples (50 μg of total protein) were dissolved with equal
volume of loading buffer (0.1 M Tris–HCl buffer (pH 6.8)
containing 0.2 M DTT, 4% SDS, 20% glycerol and 0.1%
bromophenol blue), separated on 10% SDS-PAGE and
then electrotransferred at 100 V to Immun-Blot PVDF
membrane for 1 hour at 4°C. Membranes were blocked in
TBST containing 5% non-fat milk overnight at 4°C before
incubation for 2 h at room temperature with primary
antibodies diluted in TBST containing 5% BSA. Blots
were washed extensively in TBST and incubated with
secondary antibodies in TBST/1.25% BSA for 1 h at room
temperature. The signal was detected by an enhanced
chemiluminescence method (ECL kit, Amersham), and ex-
posed to Kodak X-OMAT film (Eastman Kodak, Rochester,
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NY, U.S.A.). The intensity of the selected bands was
captured and analyzed using GeneSnap Image Analysis
Software (Syngene, U.K.). We used rabbit polyclonal
anti-human NLRP3 antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), anti-human pro-IL1-β (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and rabbit polyclonal
anti-humanGAPDHantibody(CellSignaling,Danvers,MA)
asprimaryantibodyandanti-rabbitIgGHRP-linkedantibody
(CellSignaling,USA)assecondaryantibody.
Data analysis
Data are presented as mean ± S.E.M. and analyzed by SPSS
11.0. Repeated measures analysis of variance (ANOVA)
followed by S-N-K test were used for post-hoc analysis of
differences between groups. P < 0.05 was considered a
statistically significant difference.
Results
Effects of MSU on the release of proinflammatory
cytokines IL-1β, TNFa and IL-6 from FLS
We first compared IL-1β, TNFα and IL-6 levels at differ-
ent time points in the culture media after FLS cells were
exposed to different concentrations of MSU crystals.
The levels of IL-1β, TNF-α and IL-6 triggered by 1 ug/ml,
10 ug/ml, 50 ug/ml, 100 ug/ml, 250 ug/ml and 500 ug/ml
of MSU at 6 h, 12 h, 24 h and 48 h respectively are
Figure 1 MSU induced IL-1β production in FLS. FLS were stimulated with 1 ug/ml, 10 ug/ml, 50 ug/ml, 100 ug/ml, 250 ug/ml and 500 ug/ml
of MSU at 6 h, 12 h, 24 h and 48 h respectively. The control group is treated with PBS, which is used to dilute different dosage of MSU. Supernatants were collected
for IL-1β, TNF-α and IL-6 protein detection by ELISA. The concentration of MSU 50 ug/ml induced the significant increase of IL-1β in the supernatants collected after
6 hours MSU exposure (A, p<0.05). There is no significant difference for the levels of IL-6 (B) and TNF-α (C) in the supernatant of FLS exposed to different concentration
MSU at the four time courses. Data presented are mean ± S.E.M. *represents P < 0.05 in comparison with control during statistical analysis.
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shown in Figure 1. The results indicated that 50 ug/ml of
MSU induced a significant increase in IL-1β after 6 hours,
but not at other time points (Figure 1A). The result was
re-confirmed by using serial MSU concentrations close to
50 ug/ml (Additional file 1: Figure S1). Furthermore, there
were no significant differences in levels of IL-6 (Figure 1B)
and TNFα (Figure 1C) in FLS exposed to different concen-
trations of MSU at all exposure periods.
IL-1β, TNFa and IL-6 mRNA expression in MSU treated FLS
The mRNA levels of IL-1β, TNF-α and IL-6 in FLS
treated with different doses of MSU were measured with
Q-PCR at two representative time points, short-term 6 h
and long-term 48 h. As shown in Figure 2A, 50 ug/ml of
MSU induced a 3 to 4-fold increase in IL-1β mRNA ex-
pression 6 h after treatment (Figure 2A, p<0.05), com-
pared to the control group. There was no significant
change in mRNA levels of TNF-α and IL-6 at this
time point. At the 48 h time point, different doses of
MSU did not alter mRNA levels of IL-1β, TNF-α or IL-6
(Figure 2B).
MSU mediated the consumption of storage pro-IL-1β at
the 6 h time point in the FLS
Western blot analysis showed that MSU induced pro–IL-1β
expression in FLS treated with different doses of MSU (Fig-
ure 3). A single band of the expected size (~31 kDa) for
pro–IL-1β was detected by the specific primary antibody
(Figure 3A). The increase in levels of pro–IL-1β protein was
significant after 50 ug/ml of MSU treatment compared to
the control group (Figure 3B; p<0.05). Also as shown in
Figure 3B, the other doses of MSU had no effect on
pro–IL-1β protein expression at the 6 h time point. At the
48 h time point, pro–IL-1β protein expression was unde-
tectab. in all groups (data not shown).
Effect of MSU on NLRP3 expression in FLS
NLPR3 protein level was significantly increased following
treatment with different doses of MSU at the 6 h time point
(Figure 4A; p<0.05). The band of NLPR3 was detected by
immunoblot (Figure 4B). In addition, no band was observed
when the primary antibody was omitted (data not shown).
Similar changes were observed at 48 h. At this time point
NLPR3 protein level was dramatically increased after
exposure to MSU (Figure 4C; p<0.05 and p<0.01) and the
band of NLRP3 could still be detected (Figure 4D). Accord-
ing to the Q-PCR analysis, NLPR3 mRNA level was mark-
edly increased in the FLS at 6 hours after exposure to
different doses of MSU (Figure 4E; p<0.05 and p<0.01).
Similarly, a significant increase in NLPR3 mRNA level was
also seen at 48 h (Figure 4F; p<0.05, p<0.01 and p<0.001).
Discussion
It is well-known that neutrophils and macrophages are
involved in the inflammatory reaction in gout [19,22-24]. In
addition, the role of inflammasomes in the development of a
number of diseases including gout, has been demonstrated
in these cells [17,23,25]. However, due to complex interac-
tions among various cell types, including neutrophils, macro-
phages, mast cells, endothelial cells and synovial fibroblasts
[26,27], it is possible that synovial fibroblasts also may play a
role in modulating the inflammatory response to MSU crys-
tals in gout. In this study, we addressed the role of synovial
fibroblasts in mediating the release of mature IL-1β via
activation of the NLRP3 inflammasome after exposure to
MSU. We observed that MSU increased the release of IL-1β,
but not IL-6 and TNF-a, in the supernatants of MSU-treated
Figure 2 MSU induced IL-1β mRNA expression in FLS. FLS were stimulated with 1 ug/ml, 10 ug/ml, 50 ug/ml, 100 ug/ml, 250 ug/ml and
500 ug/ml of MSU at short-term time point 6 h and long-term time point 48 h respectively. Cells were collected for IL-1β, TNF-α and IL-6 mRNA
detection by Q-PCR. The concentration of MSU 50 ug/ml induced the significant increase of IL-1β mRNA expression in the cells collected after
6 hours MSU exposure (A, p<0.05). There was no significant difference for the levels of IL-6 and TNF-α mRNA expression in the cells of FLS
exposed to different concentration MSU whether at the 6 h time point or the 48 h time point. (B) Data were three independent experiments and
presented are mean ± S.E.M. *represents P < 0.05 in comparison with control during statistical analysis.
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FLS. Low concentrations of MSU transiently triggered
an increase in mRNA and protein levels of IL-1β in FLS.
Moreover, the formation of the NLRP3 inflammasome
in the FLS was also increased after short-term treatment
(6 h) and long-term treatment (48 h) with MSU. Our
findings collectively provide a new insight into the role
of synovial fibroblasts in the pathophysiology of gout.
They suggest that synovial fibroblasts may participate in
the secretion of IL-1β via NLRP3 inflammasome forma-
tion, which could make synovial fibroblasts a potential
therapeutic target for gout.
In rheumatoid arthritis (RA), synovial fibroblasts play
an important role in the process of cartilage and bone
erosion, presumably via the synthesis of inflammatory
mediators, including chemokines [28,29], matrix metal-
loproteinases (MMPs) [30], and cytokines [31]. Peng
et al. recently showed that MSU crystals upregulated
cyclooxygenase 2 (COX-2) and interleukin 8 (IL-8) gene
expression in human synovial fibroblasts [32]. Also in
RA, elevated levels of miR-203 led to increased secretion
of MMP-1 and IL-6 via the NF-κB pathway and thereby
contributed to the activated phenotype of synovial fibro-
blasts [33]. In cultures of synovial cells from patients
with RA, blocking TNF-α with antibodies significantly
reduced the production of IL-1β, IL-6 and IL-8 [34].
Chen et al. showed that MSU, alone or in combination
with TNF-α or IL-1β, were able to significantly increase
the release of the IL-6, the chemokine CXCL8 and
MMP-1 on the activation of human FLS from RA
patients and normal control subjects [35]. Although this
is an interesting study, they did not detect the release of
IL-1β, by which was did in our present study. In sum-
mary, these studies suggest a potential role for synovial
fibroblasts in MSU-induced inflammation. Our present
study demonstrated that MSU induced a transient in-
crease in the secretion of IL-1β, which indicates a poten-
tial role for FLS in the inflammatory pathophysiology of
gout. However, no increase of IL-6 and TNF-a was
detected in synovial fibroblasts after exposure to MSU.
This may suggest that FLS play a different role in MSU
triggered inflammation compared to macrophages and
other types of immune cells. More studies are needed to
further elucidate the mechanisms.
The concentration of MSU in our study ranged from 1
ug/ml to 500 ug/ml. It was lower than that used in other
in vitro studies using macrophages or monocytes
[36-38]. 50 ug/ml of MSU only induced mature IL-1 β
secretion from FLS at the 6 h time point, which suggests
that the effect of MSU on FLS is transient. Our results
are supported by Margalit et al. [39], who showed that
prostaglandins and other arachidonic acid metabolites,
the inflammation mediation, are transiently formed after
MSU crystal injection with peak levels occurring shortly
after treatment. In the clinic, crystals are present, and
may be retrieved by aspirating the synovial fluid (SF) of
gout patients, during gout flares, but also during asymp-
tomatic periods [40,41]. However, no correlation has
been reported between the size, shape and numbers of
crystals in the SF and the severity of inflammation [42].
A potential explanation for this may be that the relation-
ship between crystal formation and inflammation is
modified by individual genomic background. Further
analysis of the factors that regulate the cellular response
to inflammatory crystals may identify potential thera-
peutic targets for gout.
IL-1β is a well-known member of the IL-1 family and
a highly inflammatory cytokine. The production and ac-
tivity of IL-1β is tightly regulated in a multi-step process.
IL-1β mRNA transcripts are rapidly expressed, and the
precursor of IL-1β is synthesized based on the activation
of Toll-like receptors (TLRs) or IL-1 signaling [43]. Our
study shows that mRNA levels of IL-1β are consistent
with pro-IL-1β protein expression in FLS exposed to
MSU. In vitro studies in human monocytes demonstrate
that the phagocytosis of MSU crystals induces the re-
lease of several cytokines, including IL-1 β, TNF-α, IL-8,
and IL-6 [44,45]. Based on in vitro studies and in vivo
animal models, gout has been identified as a prototypical
IL-1 β-dependent disease, an observation that has also
Figure 3 Changes of pro–IL-1β protein level detected by
Western blot in the cells of FLS. Western blot analysis detected
expected size protein band of pro–IL-1β (A). The pro–IL-1β protein
levels in different groups were expressed as a ratio to that of
corresponding GAPDH (B). Data presented are mean ± S.E.M.
Data were three independent experiments. *represents P < 0.05 in
comparison with control during statistical analysis.
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been confirmed by clinical studies, addressing the thera-
peutic effect of IL-1 blockage [8,46]. In addition, the
current study suggests that the release of IL-1β by
synovial fibroblasts also may be of importance in the
pathophysiology of gout.
Pro-IL-1 β needs a second signal in order to maturate
its active form, since pro- IL-1β is biologically inactive
and its processing to the active, secreted form takes
places inside the cytoplasm or in specialized secretory
lysosomes [47]. NLRP3 and its adaptor protein, ASC,
mediate caspase 1-dependent processing of certain cyto-
kines, especially IL-1β [48,49]. There is clear evidence
that MSU crystals trigger the activation of the NLRP3/
ASC/caspase1 inflammasome, an effect that culminates
in the production of IL-1β [17,50,51]. The present study
showed increased mRNA and protein levels of NLRP3 in
FLS exposed to MSU, which suggests that IL-1β secre-
tion is regulated by the NLRP3 inflammasome in FLS.
It is well-known that the release of biologically active
IL-1β needs two signals, which means the production of
mature IL-1β is tightly regulated. On the one hand, tran-
scription of the IL-1β gene and production of cytosolic
pro–IL-1β are dependent on activation of NF-kB via, for
example, TLRs. On the other hand, the second signal
leads to cleavage of pro–IL-1β by NLRP3/ASC/caspase-
1 and release of mature IL-1β [52-54]. The present study
showed a transient increase in IL-1β and NLPR3 expres-
sion in FLS. Collectively, our data suggests that cleavage
of pro- IL-1β to IL-1β is induced by the NLRP3 inflam-
masome. Migita et al. showed that MSU stimulation
resulted in the activation of caspase-1 and production
of active IL-1β and IL-1α in serum amyloid A (SAA)-
primed synovial fibroblasts, and that the effect could be
impaired in cells by silencing NLRP3 using siRNA or
inhibition of caspase-1 [55]. Together with the results of
the current study, these findings provide insight into the
molecular processes underlying the synovial inflamma-
tory condition of gout.
In addition, our present results showed that, even
though the NLRP3 expression were upregulated through-
out the whole range of concentrations and time points
used, the most effects of MSU are only observed at
50ug/mL of 6 h time points, which is essentially in
agreement with pro–IL-1β expression in the FLS cells.
Recently, Choi and Ryter [56] summarized how the
NLRP3 inflammasome is typically activated by the bimodal
signaling pathway. A Toll-like receptor (TLR)-dependent
priming step activates the NF-kB dependent transcription
of NLRP3 and the pro-forms of the pro-inflammatory cy-
tokines (i.e., IL-1β). The activation of the P2X7R receptor
by stimulation with exogenous ATP, which triggers potas-
sium ion (K+) efflux, is the second signal. Besides that, the
NLRP3 inflammsome may be activated by agents that
cause mitochondrial dysfunction and the particulates such
as monosodium urate or silica. Based on these possible
reasons, although the most effects of MSU are only ob-
served at 50ug/mL of 6 h time points, the NLRP3 expres-
sion in our present study may be existed throughout the
whole range of concentrations and time points we used. It
is currently unclear how the results of relatively short term
expression in the FLS relate to IL-1βand pro-IL-1β levels
in a condition characterised by continuing MSU exposure
during gout.
Conclusions
To our knowledge, the current study is the first to dem-
onstrate the essential role of the NLRP3 inflammasome
in synovial fibroblasts in the pathogenesis of gout. MSU
activated the NLRP3 inflammasome in FLS, which led to
the processing and maturation of pro–IL-1β into the ac-
tive form of IL-1β. MSU-induced production of IL-Iβ
was transient and partially dependent on NLRP3 inflam-
masome activation. It is hypothesized that a transient
increase in IL-1β production may enhance inflammation
and then transfer the inflammatory reaction to other cells.
The results indicate that targeting the NLRP3 inflamma-
some in FLS may be a relevant therapeutic strategy in the
treatment of gout.
Additional file
Additional file 1: Figure S1. MSU induced IL-1β production in FLS. FLS
were stimulated with 10 ug/ml, 25 ug/ml, 50 ug/ml, 75 ug/ml and 100 ug/ml
of MSU at 6 h and 48 h respectively. The control group is treated with PBS,
which is used to dilute different dosage of MSU. Supernatants were detected
for IL-1β protein by ELISA. The concentration of MSU 50 ug/ml induced the
(See figure on previous page.)
Figure 4 Changes of NLRP3 protein level detected by Western blot and mRNA level detected by Q-PCR in the FLS. FLS were stimulated
with 1 ug/ml, 10 ug/ml, 50 ug/ml, 100 ug/ml, 250 ug/ml and 500 ug/ml of MSU at short-term time point 6 h and long-term time point 48 h
respectively. Western blot analysis detected the NLPRP3 protein levels in different groups were expressed as a ratio to that of corresponding
GAPDH at the 6 h time point (A). The expected size protein band of NLPRP3 was shown at the 6 h time point (B). At the 48 h time point, the
NLPRP3 protein levels in different groups were expressed as a ratio to that of corresponding GAPDH (C). The expected size protein band of
NLPRP3 was shown at the 48 h time point (D). There was significant difference for the levels of NLRP3 mRNA expression in the cells of FLS
exposed to 50 ug/ml, 100 ug/ml, 250 ug/ml and 500 ug/ml concentration MSU at the 6 h time course (E). The dramatically increase for the NLRP3
mRNA levels in the cells of FLS exposed to all concentration MSU at the 48 h time course were detected (F). Data presented are mean ± S.E.M. Data
are three independent experiments. *represents P < 0.05, **represents P < 0.01 and ***represents P < 0.001 in comparison with control during
statistical analysis.
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significant increase of IL-1β in the supernatants collected after 6 hours MSU
exposure (A, p<0.05). There is no significant difference at the 48 h time point
(B). Data presented are mean ± S.E.M. *represents P<0.05 in comparison
with control during statistical analysis.
Abbreviations
MSU: Monosodium urate; IL-1β: Interleukin-1β; FLS: Fibroblast-like
synoviocytes; NLRP3: Nucleotide-binding domain-like receptor protein 3;
ASC: Apoptosis-associated speck like protein; MCP-1: Monocyte
chemoattractant protein-1; RA: Rheumatoid arthritis; MMPs: Matrix
metalloproteinases; COX-2: Cyclooxygenase 2; TLRs: Toll-like receptors;
SAA: Serum amyloid A.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conceived and designed the experiments: HJZ, JHQ and QL. Performed the
experiments: SCZ, XXZ, YX, LHZ and QL. Analyzed the data: HJZ, JHQ and QL.
Contributed reagents/materials/analysis tools: SCZ, XXZ, YX, LHZ and QL.
Wrote the paper: JHQ and QL. †SCZ and XXZ contributed equally. All the
authors have read and approved the final manuscript.
Acknowledgements
This study was supported by Major Project of Shanghai Science and
Technology Foundation (NO.11DJ1400101) and National Natural Science
Foundation of China (NO. 31371083, 81302573 and 81100943).
Author details
1Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai,
China. 2Institute of Rheumatology, Immunology and Allergy, Fudan
University, Shanghai, China. 3Department of Anatomy, Histology and
Embryology, Shanghai Medical College of Fudan University, 138 Yixueyuan
Road, Shanghai 200032, PR China. 4Division of Emergency Medicine, Boston
Children’s Hospital, Harvard Medical School, Boston, MA, USA. 5Key
Laboratory of Medical Imaging Computing and Computer Assisted
Intervention of Shanghai, 138 Yixueyuan Road, Shanghai 200032, PR China.
Received: 29 April 2014 Accepted: 12 March 2015
References
1. Doherty M. New insights into the epidemiology of gout. Rheumatology
(Oxford). 2009;48(2):ii2–8.
2. Schiltz C, Lioté F, Prudhommeaux F, Meunier A, Champy R, Callebert J, et al.
Monosodium urate monohydrate crystal-induced inflammation in vivo:
quantitative histomorphometric analysis of cellular events. Arthritis Rheum.
2002;46(6):1643–50.
3. Kingsbury SR, Conaghan PG, McDermott MF. The role of the NLRP3
inflammasome in gout. J Inflamm Res. 2011;4:39–49.
4. Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its
comorbidities. Nat Rev Rheumatol. 2013;9(1):13–23.
5. Dalbeth N, Haskard DO. Mechanisms of inflammation in gout.
Rheumatology (Oxford). 2005;44(9):1090–6.
6. Punzi L, Scanu A, Ramonda R, Oliviero F. Gout as autoinflammatory disease:
new mechanisms for more appropriated treatment targets. Autoimmun
Rev. 2012;12(1):66–71.
7. Gonzalez EB. An update on the pathology and clinical management of
gouty arthritis. Clin Rheumatol. 2012;31(1):13–21.
8. Mitroulis I, Skendros P, Ritis K. Targeting IL-1beta in disease; the expanding
role of NLRP3 inflammasome. Eur J Intern Med. 2010;21(3):157–63.
9. Dinarello CA. How interleukin-1β induces gouty arthritis. Arthritis Rheum.
2010;62(11):3140–4.
10. Ferraccioli G, Bracci-Laudiero L, Alivernini S, Gremese E, Tolusso B, De Benedetti F.
Interleukin-1β and interleukin-6 in arthritis animal models: roles in the early phase
of transition from acute to chronic inflammation and relevance for human
rheumatoid arthritis. Mol Med. 2010;16(11–12):552–7.
11. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of
the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive
immunity against tumors. Nat Med. 2009;15(10):1170–8.
12. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the
body. Annu Rev Immunol. 2009;27:229–65.
13. Sheedy FJ, Grebe A, Rayner KJ, Kalantari P, Ramkhelawon B, Carpenter SB,
et al. CD36 coordinates NLRP3 inflammasome activation by facilitating
intracellular nucleation of soluble ligands into particulate ligands in sterile
inflammation. Nat Immunol. 2013;14(8):812–20.
14. Freudweiler M. Study of the nature of gouty tophi. Dtsch Arch Klin Med.
1899;63:36–41.
15. McGettrick AF, O’Neill LA. NLRP3 and IL-1β in macrophages as critical regulators
of metabolic diseases. Diabetes Obes Metab. 2013;15(3):19–25.
16. Murakami Y, Akahoshi T, Hayashi I, Endo H, Kawai S, Inoue M, et al.
Induction of triggering receptor expressed on myeloid cells 1 in murine
resident peritoneal macrophages by monosodium urate monohydrate
crystals. Arthritis Rheum. 2006;54(2):455–62.
17. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid
crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237–41.
18. Martin WJ, Walton M, Harper J. Resident macrophages initiating and driving
inflammation in a monosodium urate monohydrate crystal-induced murine
peritoneal model of acute gout. Arthritis Rheum. 2009;60(1):281–9.
19. Amaral FA, Costa VV, Tavares LD, Sachs D, Coelho FM, Fagundes CT, et al.
NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception
depend on leukotriene B(4) in a murine model of gout. Arthritis Rheum.
2012;64(2):474–84.
20. Scanu A, Oliviero F, Gruaz L, Sfriso P, Pozzuoli A, Frezzato F, et al.
High-density lipoproteins downregulate CCL2 production in human
fibroblast-like synoviocytes stimulated by urate crystals. Arthritis Res Ther.
2010;12(1):R23.
21. Wijbrandts CA, Van Leuven SI, Boom HD, Gerlag DM, Stroes EG, Kastelein JJ,
et al. Sustained changes in lipid profile and macrophage migration
inhibitory factor levels after anti-tumour necrosis factor therapy in
rheumatoid arthritis. Ann Rheum Dis. 2009;68(8):1316–21.
22. Landis RC, Haskard DO. Pathogenesis of crystal-induced inflammation.
Curr Rheumatol Rep. 2001;3(1):36–41.
23. Mitroulis I, Kambas K, Ritis K. Neutrophils, IL-1β, and gout: is there a link?
Semin Immunopathol. 2013;35(4):501–12.
24. Mankan AK, Dau T, Jenne D, Hornung V. The NLRP3/ASC/Caspase-1 axis
regulates IL-1β processing in neutrophils. Eur J Immunol. 2012;42(3):710–5.
25. Guarda G, Dostert C, Staehli F, Cabalzar K, Castillo R, Tardivel A, et al. T cells
dampen innate immune responses through inhibition of NLRP1 and NLRP3
inflammasomes. Nature 9. 2009;460(7252):269–73.
26. Dalbeth N, Fransen J, Jansen TL, Neogi T, Schumacher HR, Taylor WJ.
New classification criteria for gout: a framework for progress. Rheumatology
(Oxford). 2013;52(10):1748–53.
27. Neogi T. Clinical practice. Gout N Engl J Med 3. 2011;364(5):443–52.
28. Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, et al. TWEAK is a
novel arthritogenic mediator. J Immunol 15. 2006;177(4):2610–20.
29. Chang SK, Noss EH, Chen M, Gu Z, Townsend K, Grenha R, et al.
Cadherin-11 regulates fibroblast inflammation. Proc Natl Acad Sci U S A.
2011;108(20):8402–7.
30. Thwin MM, Douni E, Arjunan P, Kollias G, Kumar PV, Gopalakrishnakone P.
Suppressive effect of secretory phospholipase A2 inhibitory peptide on
interleukin-1beta-induced matrix metalloproteinase production in rheumatoid
synovial fibroblasts, and its antiarthritic activity in hTNFtg mice. Arthritis Res Ther.
2009;11(5):R138.
31. Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis. 2002;61(2):ii84–6.
32. Peng YJ, Lee CH, Wang CC, Salter DM, Lee HS. Pycnogenol attenuates the
inflammatory and nitrosative stress on joint inflammation induced by urate
crystals. Free Radic Biol Med. 2012;52(4):765–74.
33. Stanczyk J, Ospelt C, Karouzakis E, Filer A, Raza K, Kolling C, et al. Altered
expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and
its role in fibroblast activation. Arthritis Rheum. 2011;63(2):373–81.
34. Oussirot E, Streit G, Wendling D. Infectious complications with anti-TNFalpha
therapy in rheumatic diseases: a review. Recent Pat Inflamm Allergy Drug Discov.
2007;1(1):39–47.
35. Da Chen P, Wong CK, Tam LS, Li EK, Lam CW. Activation of human
fibroblast-like synoviocytes by uric acid crystals in rheumatoid arthritis.
Cell Mol Immunol. 2011;8(6):469–78.
36. Scott P, Ma H, Viriyakosol S, Terkeltaub R, Liu-Bryan R. Engagement of CD14
mediates the inflammatory potential of monosodium urate crystals. J Immunol.
2006;177(9):6370–8.
Zheng et al. Journal of Inflammation  (2015) 12:30 Page 8 of 9
37. Yao X, Ding Z, Xia Y, Wei Z, Luo Y, Feleder C, et al. Inhibition of monosodium
urate crystal-induced inflammation by scopoletin and underlying mechanisms.
Int Immunopharmacol. 2012;14(4):454–62.
38. Mylona EE, Mouktaroudi M, Crisan TO, Makri S, Pistiki A, Georgitsi M, et al.
Enhanced interleukin-1β production of PBMCs from patients with gout after
stimulation with Toll-like receptor-2 ligands and urate crystals. Arthritis Res
Ther. 2012;4(4):R158.
39. Margalit A, Duffin KL, Shaffer AF, Gregory SA, Isakson PC. Altered arachidonic
acid metabolism in urate crystal induced inflammation. Inflammation.
1997;21(2):205–22.
40. Pascual E, Batlle-Gualda E, Martínez A, Rosas J, Vela P. Synovial fluid analysis
for diagnosis of intercritical gout. Ann Intern Med. 1999;131(10):756–9.
41. Antommattei O, Schumacher HR, Reginato AJ, Clayburne G. Prospective
study of morphology and phagocytosis of synovial fluid monosodium urate
crystals in gouty arthritis. J Rheumatol. 1984;11(6):741–4.
42. Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology
(Oxford). 2009;48(2):ii9–14.
43. Virtue A, Wang H, Yang XF. MicroRNAs and toll-like receptor/interleukin-1
receptor signaling. J Hematol Oncol. 2012;5:66.
44. Duff GW, Atkins E, Malawista SE. The fever of gout: urate crystals activate
endogenous pyrogen production from human and rabbit mononuclear
phagocytes. Trans Assoc Am Physicians. 1983;96:234–45.
45. Di Giovine FS, Malawista SE, Thornton E, Duff GW. Urate crystals stimulate
production of tumor necrosis factor alpha from human blood monocytes
and synovial cells. Cytokine mRNA and protein kinetics, and cellular
distribution. J Clin Invest. 1991;7(4):1375–81.
46. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus:
the molecular pathophysiology of autoinflammatory disease (*). Annu Rev
Immunol. 2009;27:621–68.
47. Dinarello CA. Immunological and inflammatory functions of the interleukin-1
family. Annu Rev Immunol. 2009;27:519–50.
48. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J.
NALP3 forms an IL-1beta-processing inflammasome with increased activity
in Muckle-Wells autoinflammatory disorder. Immunity. 2004;20(3):319–25.
49. Martinon F, Agostini L, Meylan E, Tschopp J. Identification of bacterial
muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome.
Curr Biol. 2004;14(21):1929–34.
50. Giamarellos-Bourboulis EJ, Mouktaroudi M, Bodar E, Van der Ven J, Kullberg
BJ, Netea MG, et al. Crystals of monosodium urate monohydrate enhance
lipopolysaccharide-induced release of interleukin 1 beta by mononuclear
cells through a caspase 1-mediated process. Ann Rheum Dis. 2009;68(2):273–8.
51. Hoffman HM, Scott P, Mueller JL, Misaghi A, Stevens S, Yancopoulos GD, et al.
Role of the leucine-rich repeat domain of cryopyrin/NALP3 in monosodium
urate crystal-induced inflammation in mice. Arthritis Rheum. 2010;62(7):2170–9.
52. Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821–32.
53. Van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA. Inflammasome
activation and IL-1β and IL-18 processing during infection. Trends Immunol.
2011;32(3):110–6.
54. Chen GY, Nuñez G. Sterile inflammation: sensing and reacting to damage.
Nat Rev Immunol. 2010;10(12):826–37.
55. Migita K, Koga T, Satomura K, Izumi M, Torigoshi T, Maeda Y, et al. Serum
amyloid A triggers the mosodium urate -mediated mature interleukin-1β
production from human synovial fibroblasts. Arthritis Res Ther. 2012;14(3):R119.
56. Choi AJ, Ryter SW. Inflammasomes: molecular regulation and implications
for metabolic and cognitive diseases. Mol Cells. 2014;37(6):441–8.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zheng et al. Journal of Inflammation  (2015) 12:30 Page 9 of 9
